INTRODUCTION

Oral and intranasal routes for procedural sedation in children undergoing diagnostic procedures like computed tomography (CT) scan, magnetic resonance imaging (MRI), ophthalmic examination, sedated auditory brainstem response and transoesophageal echocardiography are established and acceptable alternatives to injection. These routes are convenient for paediatric cancer patients undergoing radiation treatment (RT), as these children have poor performance status, are traumatised due to diagnostic and therapeutic procedures, and suffer from fear of injections. Sedation in these patients offers unique challenges as the child has to be still for accurate delivery of RT, monitoring of the remotely located child is difficult, and sedation is repeated over days.

Oral midazolam and ketamine combination is a method of procedural sedation used in radiology and the radiation suite. It is used in our institute for children undergoing fractionated RT courses.
for cancer. Although oral midazolam has good oral bioavailability and excellent anxiolysis, the distinct bad taste, associated with post-procedural delirium, restlessness, cognitive impairment and respiratory depression, limit its use. Oral ketamine produces a state of sedation, dissociative anaesthesia and analgesia, sometimes accompanied by emesis and emergence delirium. Combining midazolam with ketamine is supposed to increase the efficacy and minimise the adverse effects; however, this is not without side effects and failures. Other drawbacks relevant to the situation include unreliable absorption and vomiting, leading to unpredictable responses and neurotoxicity due to repeated use of these drugs for the course of fractionated RT. 

Dexmedetomidine is a sedative and analgesic that produces a natural sleep-like state with smooth arousal. Intranasal dexmedetomidine has been safely and effectively used in procedural sedation in CT scans, MRI with predictable results. It is also considered a safe drug in ill patients and is preferred due to its neuroprotective effect. There has been no study on intranasal dexmedetomidine as a sole agent for repetitive sedation in children. Hence, we conducted this study to compare the sedation effects of dexmedetomidine with midazolam and ketamine combinations in oncology patients. We hypothesised that intranasal dexmedetomidine will produce better sedation than the oral midazolam–ketamine combination and will be a safe alternative to the latter in paediatric cancer patients during the fractionated RT course. The primary outcome was to note the incidence of patients who could lie still in the radiation suite and successfully undergo RT in successive serial radiation exposures. The secondary outcome was to determine the sedation score achieved, medication acceptance score, time to satisfactory sedation and discharge from the hospital, the requirement of rescue sedative and any untoward side effects.

**METHODS**

Children who were planned for RT underwent routine physical examinations and investigations once the radiation protocol was advised. Children of American Society of Anesthesiologists (ASA) physical classes I, II and III, aged between 3 and 6 years, planned for RT were included in the study. Each RT session takes about 5–10 min, and the number of sessions or fractionated treatments of each RT varies. In our study, we included those who received at least 21 sessions. Children with upper respiratory tract infections, obstructive airway conditions, congenital heart disease, any other systemic disease other than cancer, allergy to study drugs and refusal to participate were excluded from the study.

The parent or the caretaker of the child was explained the procedure in the local language; after they understood the purpose, methodology, associated risks and benefits of the study, written consent was obtained and the study was carried out. A fasting protocol was followed before children were taken up for sedation in the radiotherapy holding area.

The study was a prospective randomised controlled trial conducted in a tertiary cancer hospital between October 2020 and February 2022. After obtaining institutional ethics committee permission (133-IEC-AHRCC dated 02.07.2020), the trial was registered in the Clinical Trial Registry of India (CTR/2020/09/027579). Ninety eligible children were randomised into two equal groups, group D and group MK, using a computer-generated table of random numbers and allocated into the groups through sealed opaque envelopes.

Patients in group D received 2 μg/kg of dexmedetomidine (dextomid® 100 μg/ml, Neon Lab, India) intranasally and oral honey, and those in group MK received intranasal 1 ml of saline and 0.2 mg/kg midazolam (Mezolam® 5 mg/ml Neon Lab, India) with 5 mg/kg ketamine (Aneket® 50 mg/ml Neon Lab, India) mixed with honey orally. Intranasal dexmedetomidine was prepared as per the calculated dose of the individual child by adding normal saline to make the volume 1 ml in the tuberculin syringe. Study drug preparation was carried out by an anaesthesiologist not involved in administration, assessment, data collection or the subsequent study. In both groups, 0.5 ml of the drug was deposited into each nostril equally while the child was held on the parent’s lap in the preprocedural holding area. The blood pressure (BP), heart rate (HR), respiratory rate (RR) and oxygen saturation (SpO₂) were monitored at 5-min intervals. The child’s acceptance of medication was graded using a 4-point Likert scale: 1: excellent – child accepted the premedication easily; 2: good – child complained but then accepted the medication; 3: average – child complained, initially uncooperative, but eventually accepted medication; 4: poor – child refused medication. The depth of sedation was assessed using the Ramsay Sedation Scale (RSS).

A minimum
RSS score of 3 was required to ensure motionless conditions or acceptable sedation. Assessment of sedation was done every 5 min by the observer using the RSS score and continuous monitoring by parents who reported when the child did not respond to command. The parents were allowed to hold their child on the RT couch and lay the child on the couch. The sedation level was reassessed. Children who lay still on the RT couch underwent RT; those who moved or were uncooperative, after 5–10 min were allowed to achieve a deeper sedation level. Children who could not be sedated after 20–30 min of drug administration received rescue sedation. This was administered as intravenous (IV) ketamine at 1 mg/kg, and a further top-up of 0.5 mg/kg IV was repeated if the patient moved. Physiological monitoring continued every 5 min till the patient attained an Aldrete score of 9 or more to be discharged. All patients were supplemented with oxygen via nasal prongs. The HR and BP were below 20% of the normal boundary of the age-specific normal range and were planned to be treated with atropine or ephedrine and fluids. Other side effects like oxygen desaturation, vomiting and emergence delirium were noted. Emergence delirium was assessed by the 4-point Watcha behaviour scale: 1 – calm, 2 – crying, but can be consoled, 3 – crying, cannot be consoled and 4 – agitated and thrashing around. Emergence delirium was defined on a scale of 3 and 4. For intragroup and intergroup comparison, the 21 sessions of fractionated RT were divided into three subgroups of seven consecutive radiation exposures, 1–7, 8–14 and 15–21.

We did an initial pilot study of 30 children, with 15 in each group who received either intranasal dexmedetomidine or oral midazolam–ketamine combination. The number of children who could complete initial RT was 12 (80%) in group D and 7 (46.6%) in the MK group. To keep a significant difference between the two groups with an alpha error of 5% and power of study of 90%, the estimated sample was calculated to be 42 in each group. Anticipating drop outs, we took 45 in each group. All data were entered and analysed using International Business Machines, Statistical Package for the Social Sciences (IBM, SPSS) version 21 (IBM Corp; Armonk, New York) for windows 2010. The Shapiro–Wilk normality test was used to assess the distribution of the continuous variable. Comparison of nonparametric data was done by the Mann–Whitney U test, and for normally distributed data, the Student’s t-test was employed. The Friedman test was used for intragroup repetitive analysis of categorical values, and the Kruskal–Wallis test was used for intergroup analysis. Categorical values were expressed as frequencies or percentages and compared by the Chi-square test.

**RESULTS**

The study included 90 patients, and everyone completed the study [Figure 1].

The demographic data included age, gender, ASA physical status and disease type and were comparable between the two groups [Table 1]. The incidence of successful sedation in the three successive RT subgroups; sessions: 1–7, 8–14, 15–21 was 82%, 75.6% and 66.7% in group D as compared to 40%, 24.4% and 13.3% in group MK, respectively, and the difference was significant (P < 0.001) [Tables 1 and 2]. Intragroup comparison of successful sedation did not show a significant decrease in the successive sessions of RT in group D (P = 0.234), while in group MK it was significant (P = 0.015).

Time to successful sedation and discharge was significantly less in group D as compared to group MK (P = 0.000) [Table 3].

The number of patients who required ketamine and the dose of ketamine was significantly more in group MK compared to group D (P = 0.000) [Table 4]. The rescue dose of ketamine and the number of patients requiring ketamine increased significantly in successive RT in group MK (P = 0.015) in comparison to group D, which did not show a significant increase (P = 0.234) [Table 5].

Side effects were seen in 12 (26.67%) patients as vomiting and emergence delirium in group MK, while 1 patient in group D had vomiting [Table 1].

**DISCUSSION**

In the present study, the efficacy of intranasal dexmedetomidine was compared with a combination of oral midazolam and ketamine to sedate children for repeated sessions of RT. It was observed that children who received intranasal dexmedetomidine achieved better sedation than those who received a combination of oral midazolam and ketamine. In the initial sessions, the success rate of sedation was 82% in the dexmedetomidine group. A review of published studies on intranasal dexmedetomidine in...
children showed that 2 µg/kg of the drug produced reliable procedural sedation with a success rate of 95.2% (85.9–100%).[13] In another study, 2.5 µg/kg intranasal dexmedetomidine used for sedation in CT scans resulted in desirable sedation in 67% of children. In the present study, the success rate with intranasal dexmedetomidine is closer to that described in a review of studies on this topic.[13] Our success rate of sedation in the oral midazolam–ketamine group was initially 40%, similar to the study where adequate sedation for CT scanning was achieved in 45.5% of children.[13]
In our study, the time to achieve successful sedation in the dexmedetomidine group was 16 min and 10 s, and the time to discharge was 78 min. A systematic review of 14 randomised controlled trials on intranasal dexmedetomidine for sedation in children found that the average time for onset of sedation was 15–30 min and the duration was 55 min.\(^\text{[14]}\) In yet another study, where intranasal dexmedetomidine was administered to children below 10 years, the onset time was less than 30 min and the discharge time was around 80 min.\(^\text{[22]}\) These studies show that the intranasal route of administration is efficacious and rapid, which makes it a suitable agent for procedural sedation. However, the concentration-time profiles showed that the plasma levels of dexmedetomidine fell quickly, so in procedures that were long, a repeated administration or a higher initial dose was necessary.\(^\text{[23]}\) In our study, as the duration of the procedure was within 10 min, a single bolus was appropriate.

The onset of action of oral midazolam–ketamine in our study was 22 min. In a study where oral midazolam-ketamine was administered at a similar dose, the onset time to adequate sedation was 32 min\(^\text{[5]}\) and 14 min when midazolam was used at a higher dose of 0.5 mg/kg for laceration repair.\(^\text{[24]}\) These differences in onset time can also be attributed to the metabolism of midazolam that is influenced by cytochrome P4503A (CYP3A) isoenzymes. The time to discharge in the midazolam–ketamine group in our study was 98 min 20 s, which was similar to a previous study where it was 105 min.\(^\text{[5]}\) In the dexmedetomidine group, the onset time and the time to discharge were significantly shorter than those in the midazolam–ketamine group, making it a more suitable drug for procedural sedation.

Many studies have been carried out using propofol, midazolam and/or ketamine for sedation in RT. Their repeated use has been associated with complications like sepsis, cardiovascular complications and airway complications.\(^\text{[25]}\) In one of the largest reviews done on the use of dexmedetomidine in paediatric...
patients, it was shown that dexmedetomidine has a favourable adverse effect profile with minimal untoward haemodynamic and respiratory effects, is well-tolerated and efficacious in non-invasive procedures.[26] Contrarily, some side effects due to infusions have been pointed out.[27] In our study, we witnessed no untoward effects in the dexmedetomidine group except in one patient who had vomiting. They were haemodynamically stable and maintained oxygen saturation. Nevertheless, dexmedetomidine is now occupying a special place in the perioperative management of children.[28]

There have been case reports where dexmedetomidine is used for sedation in less than 3 years old children receiving more than 20 sessions of RT. Nevertheless, we included children between 3 and 6 years of age in this study and plan to undertake a subsequent study in the lower age group.

CONCLUSION

Intranasal dexmedetomidine provides satisfactory sedation in paediatric patients receiving repeated RT. Compared to the oral midazolam–ketamine combination, the success rate of sedation in the repeated sessions is better. It is also safer, with a quicker onset of action and recovery. Although the increased need for rescue sedation in the repeated RT sessions was not significant, it cannot be overlooked. Considering its safety profile in paediatric patients, more studies may be undertaken with higher doses for more successful application in these patients.

Acknowledgements

The authors are very thankful to Ms Rachana Das, PhD student in Microeconomics, Ohio State University, USA Columbus for analysing and presenting the survey results.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Ghai B, Jain K, Saxena AK, Bhatia N, Sodhi KS. Comparison of oral midazolam with intranasal dexmedetomidine premedication for children undergoing CT imaging: A randomized, double-blind, and controlled study. Paediatr Anaesth 2017;27:37–44.
2. Cao Q, Lin Y, Xie Z, Shen W, Chen Y, Gan X, et al. Comparison of sedation by intranasal dexmedetomidine and oral chloral hydrate for paediatric ophthalmic examination. Paediatr Anaesth 2017;27:629–36.
3. Godhehere J, Harper S, Loxey T, Kirton C, Verma R, Carr S. Auditory brainstem response testing using intranasal dexmedetomidine sedation in children: A pilot study. Int J Audiol 2021;60:549–54.
4. Miller JW, Ding L, Gunter JB, Lam JE, Lin EP, Paquin JR, et al. Comparison of intranasal dexmedetomidine and oral pentobarbital sedation for transethoracic echocardiography in infants and toddlers: A prospective, randomized, double-blind trial. Anaesth Analg 2018;126:2009–16.
5. Majdinejad S, Taherian K, Esmaillian M, Khazaei M, Samaie V. Oral midazolam-ketamine versus midazolam alone for procedural sedation of children undergoing computed tomography: A randomized clinical trial. Emerg (Tehran) 2015;3:64–9.
6. Vinson AE, Houck CS. Anaesthetic exposure and neurodevelopmental outcomes in the neonate. Neoreviews 2018;19:e601–9.
7. Kumar L, Kumar A, Panikkaveetil R, Vasu BK, Rajan S, Nair SG. Efficacy of intranasal dexmedetomidine versus oral midazolam for paediatric premedication. Indian J Anaesth 2017;61:125–30.
8. Perez-Zoghbi JF, Zhu W, Grafe MR, Brambrink AM. Dexmedetomidine-mediated neuroprotection against sevofluran-induced neurotoxicity extends to several brain regions in neonatal rats. Br J Anaesth 2017;119:506–16.
9. Ramsay MA, Savege TM, Simpson BR, Goodwin R. Controlled sedation with alphaxalone-alphadoline. Br Med J 1974;2:656–9.
10. Mekitarian Filho E, Robinson F, de Carvalho WB, Gilio AE, Mason KP. Intranasal dexmedetomidine for sedation for paediatric computed tomography imaging. J Paediatr 2015;166:1313–5.
11. Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, et al. Subcommittee on screening and management of high blood pressure in children. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Paediatrics 2017;140:e20171904.
12. Bajwa SA, Costi D, Cyna AM. A comparison of emergence delirium scales following general anesthesia in children. Paediatr Anaesth 2010;20:704–11.
13. Lewis J, Bailey CR. Intranasal dexmedetomidine for sedation in children: A review. J Perioper Pract 2020;30:170–5.
14. Cronin MM, Bousfield JD, Hewett EB, McLellan I, Boulton TB. Ketamine anaesthesia for radiotherapy in small children. Anaesthesia 1972;27:135–42.
15. Harris EA. Sedation and anaesthesia options for paediatric patients in the radiation oncology suite. Int J Paediatr 2010;2010:870921.
16. Cheng C, Roemer-Becuwe C, Pereira J. When midazolam fails. J Pain Symptom Manage 2002;23:256–65.
17. Hammer GB, Philip BM, Schroeder AR, Schroeder AR, Rosen FS, Kollai PJ, et al. Prolonged infusion of dexmedetomidine for sedation following tracheal resection. Paediatr Anaesth 2005;15:616–20.
18. Walker J, MacCallum M, Fisher C, Kopcha R, Saylors R, McCall J, et al. Sedation using dexmedetomidine in pediatric burn patients. J Burn Care Res 2006;27:206–10.
19. Shukry M, Ramadhyani U. Dexmedetomidine as the primary sedative agent for brain radiation therapy in a 21-month old child. Paediatr Anaesth 2005;15:241–2.
20. Kim SK, Song MH, Lee IJ, Lee JH, Choi IC. Dexmedetomidine for sedation in pediatric patients who received more than 20 sessions of radiation therapy: Two cases report. Korean J Anaesthesiol 2016;69:627–31.
22. Ambi US, Joshi C, Ganeshnavar A, Adarsh E. Intranasal dexmedetomidine for paediatric sedation for diagnostic magnetic resonance imaging studies. Indian J Anaesth 2012;56:587-8.
23. Uusalo P, Guillaume S, Siren S, Manner T, Vilo S, Scheinin M, et al. Pharmacokinetics and sedative effects of intranasal dexmedetomidine in ambulatory paediatric patients. Anaesth Analg 2020;130:949-57.
24. Barkan S, Breitbart R, Brenner-Zada G, Feldon M, Assa A, Toledano M, et al. A double-blind, randomised, placebo-controlled trial of oral midazolam plus oral ketamine for sedation of children during laceration repair. Emerg Med J 2014;31:649-53.
25. Buchsbaum JC, McMullen KP, Douglas JG, Jackson JL, Simoneaux RV, Hines M, et al. Repetitive paediatric anaesthesia in a non-hospital setting. Int J Radiat Oncol Biol Phys 2013;85:1296-300.
26. Phan H, Nahata MC. Clinical uses of dexmedetomidine in paediatric patients. Paediatr Drugs 2008;10:49-69.
27. Bajwa SJS. Dexmedetomidine ad Ketamine-Comrades on an eternal journey! Indian J Anaesth 2021;65(Suppl 1):S1-4.
28. Malde AD, Prabhu SS, Sundaram S, Bajwa SJS. Paediatric anaesthesia practice: Has it really changed over the times? Indian J Anaesth 2022;66:621-4.